Dr Chiara Cremolini, Dr Armin Gerger, Dr Guillem Argilés discuss the Clinical Question: When to test for BRAF and what are the consequences?
Dr Chiara Cremolini, Dr Armin Gerger, Dr Guillem Argilés discuss the Clinical Question: When to test for BRAF and what are the consequences?
Dr Guillem Argilés obtained his medical degree at the Vall d’Hebron University Hospital in Barcelona, Spain. He later obtained his M.D., supervised by José Baselga M.D., in 2006 at the same institute. In 2010, he joined the Gastrointestinal Malignancies Division led by Josep Tabernero M.D., Ph.D. Dr Argilés currently works in the Gastrointestinal Malignancies and Developmental Therapeutics Divisions of the same institute, where his research is focused on chemorefractory colorectal cancer, personalized medicine, as well as the molecular biology of colorectal cancer.
Since 2012 Dr Armin Gerger is professor at the Medial University in Graz, Austria. He works as a clinical oncologist and coordinates the Subcentre for Gastrointestinal Neoplasia at the Comprehensive Cancer Centre, Graz. He leads the Pharmacogenetics Research Unit, at the Division of Clinical Oncology of the Medical University of Graz, and the Area “Cancer” of the Centre for Biomarker Research in Medicine (CBmed). Dr Gerger’s research focuses on prognostic and predictive genetic biomarkers in gastrointestinal cancer, which he developed further as a research fellow at the Norris Comprehensive Cancer Centre of the University of Southern California. Dr Gerger’s research activity is mirrored in several papers in high-ranked scientific journals and significant extramural funding.
Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer
Maximising outcomes for patients with advanced RCC
Medical experts make recommendations for best practice
The latest non-small cell lung cancer data presented at ASCO
GI oncologists review the latest data presented at ASCO 2024
Medical experts discuss the latest learnings from clinical practice